Platelet-Derived Microvesicles in Cardiovascular Diseases
نویسندگان
چکیده
منابع مشابه
Platelet-Derived Microvesicles in Cardiovascular Diseases
Microvesicles (MVs) circulating in the blood are small vesicles (100-1,000 nm in diameter) derived from membrane blebs of cells such as activated platelets, endothelial cells, and leukocytes. A growing body of evidence now supports the concept that platelet-derived microvesicles (PMVs), the most abundant MVs in the circulation, are important regulators of hemostasis, inflammation, and angiogene...
متن کاملLactadherin and clearance of platelet-derived microvesicles.
The transbilayer movement of phosphatidylserine from the inner to the outer leaflet of the membrane bilayer during platelet activation is associated with the release of procoagulant phosphatidylserine-rich small membrane vesicles called platelet-derived microvesicles. We tested the effect of lactadherin, which promotes the phagocytosis of phosphatidylserine-expressing lymphocytes and red blood ...
متن کاملMicrovesicles as cell-cell messengers in cardiovascular diseases.
Cell-cell communication has proven to be even more complex than previously thought since the discovery that extracellular vesicles serve as containers of biological information on various pathophysiological settings. Extracellular vesicles are classified into exosomes, microvesicles/microparticles, or apoptotic bodies, originating from different subcellular compartments. The cellular machinery ...
متن کاملPLATELETS AND THROMBOPOIESIS Lactadherin and clearance of platelet-derived microvesicles
The transbilayer movement of phosphatidylserine from the inner to the outer leaflet of the membrane bilayer during platelet activation is associated with the release of procoagulant phosphatidylserine-rich small membrane vesicles called platelet-derived microvesicles. We tested the effect of lactadherin, which promotes the phagocytosis of phosphatidylserineexpressing lymphocytes and red blood c...
متن کاملPlatelet function testing in cardiovascular diseases.
Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet function test demonstrates that his platelets are “resistant” to aspirin. Should his treatment be changed? Case presentation 2: Mr K. is a 60year-old man with unstable angina who takes aspirin, 81 mg/day, and clopidogrel, 75 mg/day. A platelet function test demonstrates that his platele...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Cardiovascular Medicine
سال: 2017
ISSN: 2297-055X
DOI: 10.3389/fcvm.2017.00074